This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gunderson, B. W. Articles by Rotschafer, J. C. Search for Related Content PubMed PubMed Citation Articles by Gunderson, B. W. Articles by Rotschafer, J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2003, p. 398-399, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.398-399.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Comparison of Linezolid Activities under Aerobic and Anaerobic Conditions against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus faecium

Department of Experimental and Clinical Pharmacology, The University of Minnesota College of Pharmacy, Minneapolis, Minnesota,¹ Infectious Disease Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, Colorado²

Received 4 February 2002/ Returned for modification 2 July 2002/ Accepted 18 September 2002

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium were exposed to linezolid (MIC of 2 mg/liter) under aerobic or anaerobic conditions in an in vitro pharmacodynamic model. Drug concentration and half-life were adjusted to simulate clinical dosing (600 mg twice daily) of linezolid. Linezolid produced a 2-log₁₀ killing at 24 h, and rates of killing against each of these facultative organisms as measured by mean survival time appeared similar under aerobic and anaerobic conditions.

This article has been cited by other articles:

• Boak, L. M., Li, J., Rayner, C. R., Nation, R. L. (2007). Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro Model. Antimicrob. Agents Chemother. 51: 1287-1292 [Abstract] [Full Text]  
• LaPlante, K. L., Rybak, M. J. (2004). Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 48: 4665-4672 [Abstract] [Full Text]  
• Senneville, E., Legout, L., Valette, M., Yazdanpanah, Y., Giraud, F., Beltrand, E., Obert, G., Dubreuil, L., Migaud, H., Mouton, Y. (2004). Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 54: 798-802 [Abstract] [Full Text]  
• Wagenlehner, F. M. E., Wydra, S., Onda, H., Kinzig-Schippers, M., Sorgel, F., Naber, K. G. (2003). Concentrations in Plasma, Urinary Excretion, and Bactericidal Activity of Linezolid (600 Milligrams) versus Those of Ciprofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose. Antimicrob. Agents Chemother. 47: 3789-3794 [Abstract] [Full Text]